drugset / Trial / NCT01450046
Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects
Phase 1
Completed
18 enrolled
H. Lee Moffitt Cancer Center and Research Institute
BioGene Life Science · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelPrevention
Summary
The Principal Investigator believes that Vitamin E δ-Tocotrienol will slow the progression of pancreatic cancer cells. Therefore, the investigators must determine the safety and tolerability of Vitamin E δ-Tocotrienol in healthy participants before administering to cancer patients. The investigators will do this by giving participants a dose of up to1600 mg twice a day, not to exceed 3200 mg total for 14 consecutive days.
Timeline
- Start
- 2011-10
- Primary completion
- 2013-03
- Completion
- 2016-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vitamin E δ-Tocotrienol | Unknown | 100 mg | Oral |
| Subject | Vitamin E δ-Tocotrienol | Unknown | 1600 mg | Oral |